IIPR's High Yield Remains Untenable as Tenant Defaults Persist and Life Science Pivot Advances

What happened

The latest Seeking Alpha article reiterates a hold rating on IIPR, citing persistent tenant defaults and elevated dividend cut risk as Q2 revenue and AFFO declined sequentially. AFFO coverage of the $1.90 quarterly dividend remains insufficient on a nominal basis, aligning with the DeepValue report's observation that payout exceeded AFFO since Q3 2025. Management continues to recycle capital from property sales while funding a $270M commitment to the IQHQ life-science platform, targeting >14% yields to diversify away from cannabis. Despite low balance-sheet leverage (net debt/EBITDA 0.61x) and asset backing, the forward cash flow trajectory is deteriorating, with tenant defaults expanding beyond initial names and security deposits being applied to rent. The strategic pivot to life science adds a new concentrated credit risk at a time when cannabis rent stability is not yet demonstrated, making the current ~15% yield a potential value trap rather than a buying opportunity.

Implication

The recurring theme of tenant defaults and sequential declines in revenue and AFFO undermines the current dividend's sustainability, and a cut appears more probable than not within the next 6–12 months. Balance-sheet leverage is comfortably low, but the board's explicit willingness to fund distributions from debt or equity preserves the yield at the cost of per-share value and dilutes shareholders. The pivot into life science introduces a single-counterparty concentration risk (IQHQ) that could magnify losses if that sector's fundamentals weaken, countering the diversification narrative. For existing investors, rallies above $60 offer an opportunity to reduce exposure given the skewed risk-reward; a decisive dividend cut or stabilization of AFFO above $2.00 would be needed to reconsider the thesis. New capital should await either a material price correction to around $40 or evidence that re-tenanting efforts restore AFFO coverage to near 100% before considering entry.

Thesis delta

The new article confirms and slightly intensifies the existing bearish thesis: sequential declines in Q2 revenue and AFFO show that tenant stress is not yet bottoming, and AFFO coverage remains below the dividend. The previously flagged risk of a dividend cut is now more imminent, though the balance sheet's low leverage still provides a floor to asset values. The strategic pivot to life science does not alter the near-term cash flow challenge and may add concentration risk.